Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 1 · 50%

Grades 3 and 4 adverse events · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Casirivimab/imdevimab showed no clear difference in adverse events: grade 3 to 4 until data cut‐offbÂ compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.5 [0.24, 1.02]
1 study · 2617 participants
Low

Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Casirivimab/imdevimab leads to lower adverse events: all grade until data cut‐offb compared with placebo (high certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.7 [0.61, 0.8]
1 study · 2617 participants
High